This site is intended for healthcare professionals
Innovations in MS care to improve individual disease management


Read time: 145 mins
Last updated:2nd Sep 2021
Published:11th Nov 2020

As exciting new treatment and monitoring strategies for individualising multiple sclerosis (MS) patient care emerge, join leading experts to explore:

  • Content from the 7th Virtual European Academy of Neurology (EAN) Congress 2021
  • Important topics discussed at MS relevant international congresses in 2020

Watch video footage from the Biogen satellite symposium ‘Advancing MS Therapy: Addressing the Patient Experience’, with expert Professors Til Menge, Bart Van Wijmeersch and Anne-Katrin Pröbstel from the recent EAN Congress 2021. These experts discuss the latest updates to MS treatments, with a focus on individualising MS care to achieve clinically meaningful outcomes and improve patient experiences. Professor Til Menge discusses the general considerations for MS treatment decision making and then focusses on the data that led to recent multinational approvals of intramuscular peginterferon beta-1a. Professor Anne-Katrin Pröbstel describes research underway to develop and characterise a next generation fumarate. Finally, Professor Bart Van Wijmeersch provides insights into the practicalities of administering subcutaneous natalizumab, after which all three discuss a range of issues relevant to MS treatment today, including the latest research and guidelines relevant to the pandemic.